EUVIMEDOpdag EUVIMED
Open access

Camellia diacylglycerol oil attenuates atherosclerosis and NAFLD by modulating gut microbiota and lipid metabolism in ApoE −/− mice

Sihua Wang iD, Yuchuan Chen, Lihui Qin, Ruichen Wang, Dong Fan, Yarong Wang, Fuan Zhang, Zhiwen Wu, Zhangfeng Zhong, Guozhen Cui

Journal of the Science of Food and Agriculture · 2026-09 · 106 (12) · 7097-7108

DOI: 10.1002/jsfa.70776 ↗

At a glance

Journal article in Journal of the Science of Food and Agriculture, published online on 2026-06-04. Written by Sihua Wang and 9 co-authors. Institution: Guizhou Provincial Key Laboratory of Innovation and Manufacturing for Pharmaceuticals, School of Bioengineering, Zhuhai Campus of Zunyi Medical Unive…. Major MEDLINE topics: Atherosclerosis, Non-alcoholic Fatty Liver Disease, Lipid Metabolism, Gastrointestinal Microbiome. Cited 1 times so far (Crossref); 49 references. The full text is freely available in PubMed Central. Funded by: Guizhou Province Science and Technology Program (Qiankehe support [2023] General 071), Zhuhai Medical Scientific Research Project (2520009000081), and Innovati….

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

BACKGROUND Camellia diacylglycerol oil (CDO), produced by enzymatic glycerolysis of camellia oil, is widely consumed as a functional food ingredient; however, its cardiovascular benefits remain insufficiently characterized. This study investigated the effects of CDO on high‐fat diet (HFD)‐induced atherosclerosis and non‐alcoholic fatty liver disease in ApoE −/− mice, with a particular focus on alterations in gut microbiota and metabolomic profiles. RESULTS Compared with the vehicle group, CDO supplementation (3 and 6 mL kg −1 ) reduced aortic plaque area by approximately 50% without significantly affecting body weight in the mice. CDO treatment significantly decreased serum triglycerides (TG), total cholesterol (TC) and low‐density lipoprotein cholesterol, at the same time as increasing high‐density lipoprotein cholesterol. Notably, CDO administered at 3 mL kg −1 demonstrated greater efficacy than camellia oil in improving TG and high‐density lipoprotein cholesterol levels ( P < 0.05). Furthermore, CDO supplementation significantly alleviated hepatic histopathological injury, reduced Oil Red O‐positive lipid deposition and lowered hepatic TG and TC levels compared to the vehicle group. Gut microbiota analysis revealed a decreased Firmicutes/Bacteroidetes ratio and increased relative abundances of Roseburia and Faecalibaculum in CDO‐treated mice. Metabolomic profiling further identified ether lipid metabolism and bile acid‐related pathways as potential mediators of the metabolic improvements‐induced by CDO. CONCLUSION CDO was more effective than camellia oil in mitigating HFD‐induced atherosclerosis and non‐alcoholic fatty liver disease in ApoE −/− mice, most likely through coordinated modulation of the gut–liver–vascular axis. These findings support the potential of CDO as a functional food ingredient for cardiovascular risk reduction and warrant further validation in human studies. © 2026 Society of Chemical Industry.

Subjects

MeSH terms (MEDLINE)

AtherosclerosisNon-alcoholic Fatty Liver DiseaseLipid MetabolismGastrointestinal MicrobiomeApolipoproteins ECamelliaPlant OilsDiglyceridesAnimalsMiceMaleHumansMice, Inbred C57BLTriglyceridesLiverDiet, High-FatBacteriaMice, KnockoutCholesterol

Author keywords

atherosclerosiscamellia diacylglycerol oilgut microbiotalipid metabolismnon‐alcoholic fatty liver disease

Substances

Apolipoproteins EPlant OilsDiglyceridesTriglyceridesCholesterol

Authors and institutions

  • Guizhou Provincial Key Laboratory of Innovation and Manufacturing for Pharmaceuticals, School of Bioengineering, Zhuhai Campus of Zunyi Medical University, Zhuhai, China.
  • Guizhou Camellia Oil Engineering Technology Research Center, Tongren, China.
  • Department of Pathophysiology, Zhuhai Campus of Zunyi Medical University, Zhuhai, China.
  • Macao Centre for Research and Development in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao SAR, China.

ORCID profiles: Sihua Wang

Funding

  • Guizhou Province Science and Technology Program (Qiankehe support [2023] General 071), Zhuhai Medical Scientific Research Project (2520009000081), and Innovati…

Cite

APA

Wang, S., Chen, Y., Qin, L., Wang, R., Fan, D., Wang, Y., Zhang, F., Wu, Z., Zhong, Z., & Cui, G. (2026). Camellia diacylglycerol oil attenuates atherosclerosis and NAFLD by modulating gut microbiota and lipid metabolism in ApoE −/− mice. Journal of the Science of Food and Agriculture, 106(12), 7097-7108. https://doi.org/10.1002/jsfa.70776

Vancouver

Wang S, Chen Y, Qin L, Wang R, Fan D, Wang Y, et al. Camellia diacylglycerol oil attenuates atherosclerosis and NAFLD by modulating gut microbiota and lipid metabolism in ApoE −/− mice. Journal of the Science of Food and Agriculture. 2026;106(12):7097-7108. doi:10.1002/jsfa.70776

BibTeX
@article{Wang2026,
  author = {Wang, Sihua and Chen, Yuchuan and Qin, Lihui and Wang, Ruichen and Fan, Dong and Wang, Yarong and Zhang, Fuan and Wu, Zhiwen and Zhong, Zhangfeng and Cui, Guozhen},
  title = {Camellia diacylglycerol oil attenuates atherosclerosis and NAFLD by modulating gut microbiota and lipid metabolism in ApoE −/− mice},
  journal = {Journal of the Science of Food and Agriculture},
  year = {2026},
  volume = {106},
  number = {12},
  pages = {7097--7108},
  doi = {10.1002/jsfa.70776}
}
Start for free →